Science Explorer Back to mapMap
Discussion
Researcher · Simcere Pharmaceutical (China) · China

Mengmeng Li

Mengmeng Li publishes mostly in Pulmonary and Respiratory Medicine, Molecular Biology and Oncology, on topics such as Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment and MicroRNA in disease regulation.

ORCID 0000-0002-8623-331X OpenAlex
World rank
#5,254,782
of 7,710,434 ranked researchers
Rank in China
#774,874
of 978,568
Works
29
Citations
278
Citations per work
9.6
h-index
8
i10-index 7Top 64% in Pulmonary and Respiratory Medicine
Mengmeng Li

What does Mengmeng Li research?

Mengmeng Li's work is mostly in Medicine (34%), Biochemistry, Genetics and Molecular Biology (21%), Immunology and Microbiology (7%).

Everything else: 11 works · 37.9% of their workHealth Sciences: 10 works · 34.1% of their workMedicine: 10 works · 34.1% of their workPulmonary and Respiratory Medicine: 6 works · 20.7% of their workOncology: 2 works · 8.5% of their workRheumatology: 1 works · 4.9% of their workLife Sciences: 8 works · 28.0% of their workBiochemistry, Genetics and Molecular Biology: 6 works · 20.7% of their workMolecular Biology: 4 works · 14.6% of their workCancer Research: 2 works · 6.1% of their workImmunology and Microbiology: 2 works · 7.3% of their workImmunology: 2 works · 7.3% of their workTHEIR WORKMengmeng Li29works
Life Sciences28%Health Sciences34%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
  1. Everything else1137.9%
    1. Medicine1034.1%
    1. Biochemistry, Genetics and Molecular Biology620.7%
    2. Immunology and Microbiology27.3%
  1. 1Pulmonary and Respiratory Medicine21% of their works
  2. 2Molecular Biology15% of their works
  3. 3Oncology8% of their works
  4. 4Immunology7% of their works
  5. 5Cancer Research6% of their works
  6. 6Rheumatology5% of their works

Research topics

Which keywords describe Mengmeng Li's research?

The keywords of their largest research topics: Clinical Trials, Targeted Therapy, ALK Inhibitors, EGFR Mutations, Chemotherapy, Cancer, Gene Expression and CT Screening.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 21 words, with their numbers
  1. Clinical Trials102 topics
  2. Targeted Therapy102 topics
  3. ALK Inhibitors81 topic
  4. EGFR Mutations81 topic
  5. Chemotherapy52 topics
  6. Cancer42 topics
  7. Gene Expression42 topics
  8. CT Screening31 topic
  9. Lung Cancer31 topic
  10. Assisted Reproductive Technology21 topic
  11. Cell Death21 topic
  12. Ferroptosis21 topic
  13. Genomic Profiles21 topic
  14. In Vitro Fertilization21 topic
  15. Innate Immunity21 topic
  16. Medical Imaging21 topic
  17. MicroRNA21 topic
  18. Radiomics21 topic
  19. Regulation21 topic
  20. Small-Cell Lung Cancer21 topic
  21. Viral Infection21 topic

Where does Mengmeng Li work?

Mengmeng Li's main affiliation in the publication record is Simcere Pharmaceutical (China), China.

How many publications and citations does Mengmeng Li have?

OpenAlex counts 29 works and 278 citations for Mengmeng Li, an h-index of 8, ranking #5,254,782 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Other researchers named Mengmeng Li

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Mengmeng Li. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.